Pharmala Biotech Holdings Inc. (CSE:MDMA)

Market Cap	14.39M
Revenue (ttm)	420.81K
Net Income (ttm)	-2.04M
Shares Out	106.60M
EPS (ttm)	-0.02
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	144,662
Average Volume	311,038
Open	0.1250
Previous Close	0.1250
Day's Range	0.1200 - 0.1350
52-Week Range	0.0650 - 0.3400
Beta	0.94
RSI	53.82
Earnings Date	Jul 25, 2025

About Pharmala Biotech Holdings

Pharmala Biotech Holdings Inc., doing business as PharmAla, a biotechnology company, engages in the development, manufacture, and sale of MDMA and MDXX class molecules in service to the burgeoning clinical research community. It offers its MDMA drug active pharmaceutical ingredients under the LaNeo brand. The company is headquartered in Vancouver, Canada.

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Nicholas Kadysh
• Country: Canada
• Stock Exchange: Canadian Securities Exchange
• Ticker Symbol: MDMA

Financial Performance

In 2024, Pharmala Biotech Holdings's revenue was 1.04 million, an increase of 94.60% compared to the previous year's 532,003. Losses were -823,596, 5.61% more than in 2023.